be_ixf;ym_202604 d_24; ct_50

Latest Insights on REAL

david and goliath amazon Amazon’s $1 Trillion Playbook: How to Buy the Next Market Disruptor February 6, 2020 by Charles Mizrahi American Investor Today, Trading Strategies Today, Amazon and Netflix are known as industry disruptors. But in their early days, they were considered underdogs going up against giant brick-and-mortar retail chains. Today, Charles Mizrahi uncovers the one secret that underpins “underdogs” such as Netflix and Amazon.
The latest U.S. private payrolls data are in, and the economy is looking stronger than ever! (If you judge things solely on jobs data, that is.) Jobs Wow Wall Street … Disney, Not so Much February 5, 2020 by Joseph Hargett Great Stuff Keepin’ the Bulls Happy I live for moments like today, dear reader. The latest U.S. private payrolls data are in, and the economy is looking stronger than ever! (If you judge things solely on jobs data, that is.) Yes, I know I preach a bit of doom and gloom from time to time, but someone […]
If you don’t think the Wuhan coronavirus outbreak will impact the U.S. economy, I’ve got some bad news for you. The Chinese Time Bomb; Tesla Tendies Time February 4, 2020 by Joseph Hargett Great Stuff The Ticking Chinese Time Bomb Sorry to ruin your bull market party, but there’s an issue we need to discuss … like, right now. I’m talking about the Wuhan coronavirus and the U.S.-China “phase 1” trade deal. Here’s the thing: More than 20,000 Chinese are infected with the Wuhan virus, with some 427 dead. Tens […]
Billionaire Ken Griffin’s strategy is an example of how to grow wealth fast. It’s how he made his $13 billion fortune. Invest Like a Billionaire With 1 Simple Trick February 4, 2020 by Michael Carr Investing, Trading Strategies, Winning Investor Daily Billionaire Ken Griffin’s strategy is an example of how to grow wealth fast. It’s how he made his $13 billion fortune.
abbvie stock Profit From AbbVie’s Struggles Today February 4, 2020 by Chad Shoop American Investor Today, Stocks Abbvie’s flagship medication Humira is a huge seller in the U.S. and abroad. But as more companies develop their own versions, will Abbvie’s stock crater in the face of tighter competition? I’ll review Abbvie’s balance sheet and fundamentals to let you know whether you should expect the stock to surge — or fall even further in 2020.

Newsletter Sign Up

Sponsored

CS Care Video

MEET OUR EXPERTS

WHAT READERS ARE SAYING..

"I couldn’t believe it … in just 2 months, I made $298,506 on one stock – that’s a 24% gain!"

- John B.

“I started with $215,000 in Nov. 2018, It is now over 800,000. So very happy with Banyan Hill Publishing.”

- Larry K.

“Loving the 238% gain after I bought your recommendation in Sept. 2019! This week (July 21, 2020) will be my 1 year anniversary with your amazing team … thanks for the life-changing work you all do! Between all your services, 14 triple-digit gains, the greatest at 358%!"

- Matt

Share This